Olaparib recommended for BRCA-mutated metastatic CRPC
medwireNews: Olaparib has been granted a positive opinion by the EMA for use in patients with metastatic castration-resistant prostate cancer (CRPC) with a somatic or germline BRCA1 or BRCA mutation.
The Committee for Medicinal Products for Human Use recommends marketing authorization for the PARP inhibitor after disease progression on treatment that has included a new hormonal agent.
The announcement follows the US FDA’s decision to approve both olaparib and rucaparib in a similar indication.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group